Brief: Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results From Ongoing Phase 2 Study Of ANAVEX®3-71 For The Treatment Of Schizophrenia

Anavex Life Sciences

17/10/2024 12:40

Oct 17 (Reuters) - Anavex Life Sciences Corp  AVXL.O :
    * ANAVEX LIFE SCIENCES ANNOUNCES ENCOURAGING PRELIMINARY
BIOMARKER
RESULTS FROM ONGOING PHASE 2 STUDY OF ANAVEX®3-71 FOR THE
TREATMENT OF SCHIZOPHRENIA
    * ANAVEX LIFE SCIENCES CORP - ANAVEX(®)3-71 WELL TOLERATED,
NO
SERIOUS ADVERSE EVENTS
    * ANAVEX LIFE SCIENCES CORP - PRELIMINARY RESULTS SHOW
DOSE-DEPENDENT EFFECT ON TWO KEY EEG BIOMARKERS
    * ANAVEX LIFE SCIENCES CORP - DATA FROM PART B EXPECTED IN
FIRST
HALF OF 2025

Source text for Eikon:  ID:nGNXyd5QK 
Further company coverage:  AVXL.O 

 ((Reuters.Briefs@thomsonreuters.com;))